CLINICAL_TRIALS
trial_result
· 2025-12-31
Clinical Trial Update: Multiple Ascending Dose Phase 1 Study of ALA-3000 [Phase 1]
Summary
Phase 1 multiple ascending dose study of ALA-3000 in treatment-resistant depression has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alar Pharmaceuticals Inc. | Conditions: Treatment Resistant Depression | Phase 1 | Status: COMPLETED